Tumor selectivity and transcriptional activation by azelaic bishydroxamic acid (cas 18992-11-5) in human melanocytic cells

Add time:07/18/2019    Source:sciencedirect.com

azelaic bishydroxamic acid (cas 18992-11-5) (ABHA), a potent differentiating agent for lymphoid cells, was selectively toxic for 5 human tumor cell lines and transformed human melanocytes and keratinocytes (dose for 37% survival, D37, 30–100 μg/mL) compared with normal cells (melanocytes, fibroblasts; D37 > 300 μg/mL). Dendritic morphology was the only indicator found for increased differentiation, markers for the pigmentation pathway being unchanged or inhibited by ABHA. In contrast to hexamethylene bisacetamide and azelaic acid, ABHA significantly increased the HIV LTR, SV40 and c-fos promoter activities during a 24 hr treatment. Metallothionein promoter activity was enhanced by 5 hr treatment with ABHA in a sensitive melanoma cell line (MM96L) but was inhibited in a more resistant line (HeLa); c-fos promoter activity was inhibited in HeLa during this time. Transcription from a p53 binding response element was inhibited in MM96L by a 24 hr ABHA treatment but enhanced in HeLa. ABHA may represent a structural prototype for designing more potent and selective anti-melanoma agents.

We also recommend Trading Suppliers and Manufacturers of azelaic bishydroxamic acid (cas 18992-11-5). Pls Click Website Link as below: cas 18992-11-5 suppliers

Prev:Reagent-free continuous thermal tert-butyl ester deprotection
Next:Copper(I)-catalyzed benzylic C(sp3)–H geminal difunctionalization: Successive oxidative intramolecular amidation and hydroxylation)